MedTrace Logo

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

NCT02755714 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-19

No results posted yet for this study

Summary

Exercise Induced Laryngeal Obstruction (EILO) is a condition not uncommon in otherwise healthy young people. EILO is caused by posteromedial collapse of supraglottic structures or medialization of the vocal folds, or both, during high intensity exercise. There are currently no treatments available that is properly evidence based. However, case reports suggest a possible effect from the "asthma drug" Ipratropium Bromide (Atrovent®). The current project is an open label pilot study, aiming to test if Atrovent can influence the occurence of EILO, either postponing the onset during exercise or fully prevent the condition to occur.

Conditions

  • Exercise Induced Laryngeal Obstruction (EILO)

Interventions

DRUG

Ipratropium bromide spray

The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)

Sponsors & Collaborators

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • BERG ANSGAR, MD and PhD · HAUKELAND UNIVERSITY HOSPITAL, PEDIATRIC DEPARTMENT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02755714 on ClinicalTrials.gov